Updates on Clinical Studies and Milestone Revenues - Research Report on Cyberonics, West, Nektar, OraSure, and Akorn PR Newswire NEW YORK, November 12, 2013 NEW YORK, November 12, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Cyberonics, Inc. (NASDAQ: CYBX), West Pharmaceutical Services, Inc. (NYSE: WST), Nektar Therapeutics (NASDAQ: NKTR), OraSure Technologies, Inc. (NASDAQ: OSUR), and Akorn, Inc. (NASDAQ: AKRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Cyberonics, Inc. Research Report On November 7, 2013, Cyberonics, Inc. (Cyberonics) announced that it will release its Q2 FY 2014 financial results (period ended October 25, 2013) on November 21, 2013, before regular market trading hours. On the same day, the Company will host a conference call at 8:00 a.m. CT / 9:00 a.m. ET to discuss the results. The Full Research Report on Cyberonics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/ad51_CYBX] West Pharmaceutical Services, Inc. Research Report On November 7, 2013, West Pharmaceutical Services, Inc. (West) announced that it has completed a preliminary study of its SmartDose technology platform, incorporating a Daikyo Crystal Zenith (CZ) cartridge. The Company informed that the study evaluated multiple attributes of the technology and subjects' experience with the self-application process. "We believe our efforts to develop the SmartDose technology platform system are important, because we see an unmet need for high-volume subcutaneous delivery of viscous or sensitive drug products, which may require longer injection times," said Paul Norton, Vice President of Self-Injection Systems at West. Norton continued, "The flexibility of CZ allows it to be optimized for use with the SmartDose platform and makes it possible to utilize these technologies for the next generation of self-administered protein-based drugs. This is an important step as we seek to develop a complete drug delivery system incorporating the benefits of Daikyo CZ as an alternative to glass for biotech products." The Full Research Report on West Pharmaceutical Services, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/39a2_WST] Nektar Therapeutics Research Report On November 7, 2013, Nektar Therapeutics (Nektar) reported Q3 2013 financial results. In Q3 2013, the Company generated revenues of $60.9 million, up 229.7% YoY, primarily due to a $25.0 million milestone related to the acceptance of the naloxegol MAA filing in Europe and increase in products sales. For Q3 2013, net loss was $16.5 million, or $0.14 per diluted share, compared with a net loss of $43.5 million, or $0.38 per diluted share, in Q3 2012. "Nektar continues to have a very productive year achieving significant milestones with both our partnered programs and proprietary pipeline," said Howard W. Robin, President and CEO of Nektar. "For naloxegol, the MAA in Europe and NDS in Canada are now accepted for filing and the NDA in the U.S. was submitted for filing in mid-September. Naloxegol could be the first once-daily oral peripheral opioid antagonist approved to treat opioid-induced constipation. BAX 855, Baxter's longer-acting PEGylated Factor VIII therapy, which is in Phase 3, remains on track for a 2014 BLA filing." The Full Research Report on Nektar Therapeutics - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/3421_NKTR] OraSure Technologies, Inc. Research Report On November 6, 2013, OraSure Technologies, Inc. (OraSure) reported Q3 2013 financial results. In Q3 2013, consolidated net revenues were $24.7 million, up 11.6% YoY, primarily due to sales of OraQuick In-Home HIV test, as well as record revenues from DNA Genotek, OraSure's molecular collection systems subsidiary. In Q3 2013, consolidated net loss was $1.9 million, or $0.03 per diluted share, compared with a net loss of $2.4 million, or $0.04 per diluted share, in Q3 2012. "Our molecular collection systems business continues to deliver strong growth and we are encouraged by the higher sales of our OraQuick® HCV test. We have also launched a new targeted promotional campaign for the OraQuick® In-Home HIV test in an effort to accelerate growth of that important product line," said Douglas A. Michels, President and CEO of OraSure. The Full Research Report on OraSure Technologies, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/ef88_OSUR] Akorn, Inc. Research Report On November 5, 2013, Akorn, Inc. (Akorn) reported Q3 2013 financial results. In Q3 2013, the Company achieved record consolidated revenues of $81.9 million, up 17.6% YoY due to the sales of new products that were launched in late 2012, as well as increases in sales volume for existing products, offset by decreases in the average sales price for existing products and lower sales from the Company's subsidiary in India. For Q3 2013, net income was $12.2 million, or $0.11 per diluted share, compared with $13.8 million, or $0.12 per diluted share, in Q3 2012. "We are pleased with our third quarter results as we continue to demonstrate a strong double-digit growth rate in our top-line despite the delays in getting regulatory approvals from the U.S. Food and Drug Administration. In addition, we had a solid quarter of earnings and cash flow. We continue to build our pipeline with the increased investment in R&D and are excited about the acquisition of Hi-Tech which we expect to close in the first quarter of 2014. We expect to have a strong finish to the year 2013 as we expect to be at the upper end of our current revenue guidance," said Raj Rai, CEO of Akorn. The Full Research Report on Akorn, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/900c_AKRX] EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.analystscorner.com/ SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
NY Gov. Cuomo Says MTA Systemwide Service Expected This Morning
Updates on Clinical Studies and Milestone Revenues - Research Report on Cyberonics, West, Nektar, OraSure, and Akorn
Press spacebar to pause and continue. Press esc to stop.